Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

Impact of commonly used drugs on the composition and metabolic function of the gut microbiota.

Vich Vila A, Collij V, Sanna S, Sinha T, Imhann F, Bourgonje AR, Mujagic Z, Jonkers DMAE, Masclee AAM, Fu J, Kurilshikov A, Wijmenga C, Zhernakova A, Weersma RK.

Nat Commun. 2020 Jan 17;11(1):362. doi: 10.1038/s41467-019-14177-z.

2.

Intestinal barrier function is maintained with aging - a comprehensive study in healthy subjects and irritable bowel syndrome patients.

Wilms E, Troost FJ, Elizalde M, Winkens B, de Vos P, Mujagic Z, Jonkers DMAE, Masclee AAM.

Sci Rep. 2020 Jan 16;10(1):475. doi: 10.1038/s41598-019-57106-2.

3.

Quality of life in irritable bowel syndrome: Authors' reply.

Mujagic Z, Weerts ZZRM, Vork L, Leue C, Kruimel JW, Hesselink M, Muris JWM, Jonkers DMAE, Masclee AAM, Keszthelyi D.

Neurogastroenterol Motil. 2020 Jan;32(1):e13729. doi: 10.1111/nmo.13729. No abstract available.

PMID:
31854094
4.

Stool Consistency: Looking Beyond the Bristol Stool Form Scale.

Vork L, Wilms E, Penders J, Jonkers DMAE.

J Neurogastroenterol Motil. 2019 Oct 30;25(4):625. doi: 10.5056/jnm19086. No abstract available.

5.

Sugar Beet Pectin Supplementation Did Not Alter Profiles of Fecal Microbiota and Exhaled Breath in Healthy Young Adults and Healthy Elderly.

An R, Wilms E, Smolinska A, Hermes GDA, Masclee AAM, de Vos P, Schols HA, van Schooten FJ, Smidt H, Jonkers DMAE, Zoetendal EG, Troost FJ.

Nutrients. 2019 Sep 12;11(9). pii: E2193. doi: 10.3390/nu11092193.

6.

Ambient air quality as risk factor for microscopic colitis - A geographic information system (GIS) study.

Verhaegh BPM, Bijnens EM, van den Heuvel TRA, Goudkade D, Zeegers MP, Nawrot TS, Masclee AAM, Jonkers DMAE, Pierik MJ.

Environ Res. 2019 Nov;178:108710. doi: 10.1016/j.envres.2019.108710. Epub 2019 Aug 28.

PMID:
31520828
7.

Efficacy and Safety of Peppermint Oil in a Randomized, Double-Blind Trial of Patients With Irritable Bowel Syndrome.

Weerts ZZRM, Masclee AAM, Witteman BJM, Clemens CHM, Winkens B, Brouwers JRBJ, Frijlink HW, Muris JWM, De Wit NJ, Essers BAB, Tack J, Snijkers JTW, Bours AMH, de Ruiter-van der Ploeg AS, Jonkers DMAE, Keszthelyi D.

Gastroenterology. 2020 Jan;158(1):123-136. doi: 10.1053/j.gastro.2019.08.026. Epub 2019 Aug 27.

PMID:
31470006
8.

The Impact of Pectin Supplementation on Intestinal Barrier Function in Healthy Young Adults and Healthy Elderly.

Wilms E, Jonkers DMAE, Savelkoul HFJ, Elizalde M, Tischmann L, de Vos P, Masclee AAM, Troost FJ.

Nutrients. 2019 Jul 9;11(7). pii: E1554. doi: 10.3390/nu11071554.

9.

Risk of impaired nutritional status and flare occurrence in IBD outpatients.

Spooren CEGM, Wintjens DSJ, de Jong MJ, van der Meulen-de Jong AE, Romberg-Camps MJ, Becx MC, Maljaars JP, van Bodegraven AA, Mahmmod N, Markus T, Hameeteman WM, Masclee AAM, Winkens B, Jonkers DMAE, Pierik MJ.

Dig Liver Dis. 2019 Sep;51(9):1265-1269. doi: 10.1016/j.dld.2019.05.024. Epub 2019 Jun 15.

PMID:
31213405
10.

Reduction in IBS symptom severity is not paralleled by improvement in quality of life in patients with irritable bowel syndrome.

Weerts ZZRM, Vork L, Mujagic Z, Keszthelyi D, Hesselink MAM, Kruimel J, Leue C, Muris JWM, Jonkers DMAE, Masclee AAM.

Neurogastroenterol Motil. 2019 Aug;31(8):e13629. doi: 10.1111/nmo.13629. Epub 2019 May 22.

11.

Faecal Microbiota Dynamics and their Relation to Disease Course in Crohn's Disease.

Galazzo G, Tedjo DI, Wintjens DSJ, Savelkoul PHM, Masclee AAM, Bodelier AGL, Pierik MJ, Jonkers DMAE, Penders J.

J Crohns Colitis. 2019 Sep 27;13(10):1273-1282. doi: 10.1093/ecco-jcc/jjz049.

12.

Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases.

Sanna S, van Zuydam NR, Mahajan A, Kurilshikov A, Vich Vila A, Võsa U, Mujagic Z, Masclee AAM, Jonkers DMAE, Oosting M, Joosten LAB, Netea MG, Franke L, Zhernakova A, Fu J, Wijmenga C, McCarthy MI.

Nat Genet. 2019 Apr;51(4):600-605. doi: 10.1038/s41588-019-0350-x. Epub 2019 Feb 18.

13.

Modulation of Intestinal Epithelial Permeability by Plasma from Patients with Crohn's Disease in a Three-dimensional Cell Culture Model.

Xu P, Elamin E, Elizalde M, Bours PPHA, Pierik MJ, Masclee AAM, Jonkers DMAE.

Sci Rep. 2019 Feb 14;9(1):2030. doi: 10.1038/s41598-018-38322-8.

14.

Impact of early events and lifestyle on the gut microbiota and metabolic phenotypes in young school-age children.

Zhong H, Penders J, Shi Z, Ren H, Cai K, Fang C, Ding Q, Thijs C, Blaak EE, Stehouwer CDA, Xu X, Yang H, Wang J, Wang J, Jonkers DMAE, Masclee AAM, Brix S, Li J, Arts ICW, Kristiansen K.

Microbiome. 2019 Jan 4;7(1):2. doi: 10.1186/s40168-018-0608-z.

15.

Crashing NASH in Patients Listed for Bariatric Surgery.

De Munck TJI, Verhaegh PLM, Verbeek J, Verheij J, Greve JW, Jonkers DMAE, Masclee AAM, Koek GH.

Obes Surg. 2019 Mar;29(3):1012-1014. doi: 10.1007/s11695-018-03637-y. No abstract available.

PMID:
30604081
16.

Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome.

Vich Vila A, Imhann F, Collij V, Jankipersadsing SA, Gurry T, Mujagic Z, Kurilshikov A, Bonder MJ, Jiang X, Tigchelaar EF, Dekens J, Peters V, Voskuil MD, Visschedijk MC, van Dullemen HM, Keszthelyi D, Swertz MA, Franke L, Alberts R, Festen EAM, Dijkstra G, Masclee AAM, Hofker MH, Xavier RJ, Alm EJ, Fu J, Wijmenga C, Jonkers DMAE, Zhernakova A, Weersma RK.

Sci Transl Med. 2018 Dec 19;10(472). pii: eaap8914. doi: 10.1126/scitranslmed.aap8914.

PMID:
30567928
17.

Development and Validation of a Patient-reported Score to Screen for Mucosal Inflammation in Inflammatory Bowel Disease.

de Jong MJ, Roosen D, Degens JHRJ, van den Heuvel TRA, Romberg-Camps M, Hameeteman W, Bodelier AGL, Romanko I, Lukas M, Winkens B, Markus T, Masclee AAM, van Tubergen A, Jonkers DMAE, Pierik MJ.

J Crohns Colitis. 2019 Apr 26;13(5):555-563. doi: 10.1093/ecco-jcc/jjy196.

PMID:
30476099
18.

Novel Perceived Stress and Life Events Precede Flares of Inflammatory Bowel Disease: A Prospective 12-Month Follow-Up Study.

Wintjens DSJ, de Jong MJ, van der Meulen-de Jong AE, Romberg-Camps MJ, Becx MC, Maljaars JP, van Bodegraven AA, Mahmmod N, Markus T, Haans J, Masclee AAM, Winkens B, Jonkers DMAE, Pierik MJ.

J Crohns Colitis. 2019 Mar 30;13(4):410-416. doi: 10.1093/ecco-jcc/jjy177.

PMID:
30371776
19.

A Novel Ileocolonic Release Peppermint Oil Capsule for Treatment of Irritable Bowel Syndrome: A Phase I Study in Healthy Volunteers.

Weerts ZZRM, Keszthelyi D, Vork L, Aendekerk NCP, Frijlink HW, Brouwers JRBJ, Neef C, Jonkers DMAE, Masclee AAM.

Adv Ther. 2018 Nov;35(11):1965-1978. doi: 10.1007/s12325-018-0802-1. Epub 2018 Oct 4.

PMID:
30284674
20.

Volatile metabolites in breath strongly correlate with gut microbiome in CD patients.

Smolinska A, Tedjo DI, Blanchet L, Bodelier A, Pierik MJ, Masclee AAM, Dallinga J, Savelkoul PHM, Jonkers DMAE, Penders J, van Schooten FJ.

Anal Chim Acta. 2018 Sep 26;1025:1-11. doi: 10.1016/j.aca.2018.03.046. Epub 2018 Mar 30.

21.

Incidence and Classification of Postcolonoscopy Colorectal Cancers in Inflammatory Bowel Disease: A Dutch Population-Based Cohort Study.

Wintjens DSJ, Bogie RMM, van den Heuvel TRA, le Clercq CMC, Oostenbrug LE, Romberg-Camps MJL, Straathof JW, Stassen LPS, Masclee AAM, Jonkers DMAE, Sanduleanu-Dascalescu S, Pierik MJ.

J Crohns Colitis. 2018 Jun 28;12(7):777-783. doi: 10.1093/ecco-jcc/jjy044.

PMID:
29648663
22.

Corticosteroid Sparing in Inflammatory Bowel Disease is More Often Achieved in the Immunomodulator and Biological Era-Results from the Dutch Population-Based IBDSL Cohort.

Jeuring SFG, Biemans VBC, van den Heuvel TRA, Zeegers MP, Hameeteman WH, Romberg-Camps MJL, Oostenbrug LE, Masclee AAM, Jonkers DMAE, Pierik MJ.

Am J Gastroenterol. 2018 Mar;113(3):384-395. doi: 10.1038/ajg.2017.482. Epub 2018 Jan 9.

PMID:
29317770
23.

Patient-Reported Outcome Measures for Use in Clinical Trials and Clinical Practice in Inflammatory Bowel Diseases: A Systematic Review.

de Jong MJ, Huibregtse R, Masclee AAM, Jonkers DMAE, Pierik MJ.

Clin Gastroenterol Hepatol. 2018 May;16(5):648-663.e3. doi: 10.1016/j.cgh.2017.10.019. Epub 2017 Oct 23.

PMID:
29074448
24.

[Changes in the treatment of Crohn's disease: fewer hospitalizations, less surgery, and reduced glucocorticoid use].

Jeuring SFG, van den Heuvel TRA, Zeegers MP, Haans JJ, Romberg-Camps MJL, Oostenbrug LE, Stassen LPS, Masclee AAM, Jonkers DMAE, Pierik MJ.

Ned Tijdschr Geneeskd. 2017;161:D1641. Dutch.

PMID:
28854988
25.

Rome III vs Rome IV criteria for irritable bowel syndrome: A comparison of clinical characteristics in a large cohort study.

Vork L, Weerts ZZRM, Mujagic Z, Kruimel JW, Hesselink MAM, Muris JWM, Keszthelyi D, Jonkers DMAE, Masclee AAM.

Neurogastroenterol Motil. 2018 Feb;30(2). doi: 10.1111/nmo.13189. Epub 2017 Aug 14.

PMID:
28804974
26.

Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial.

de Jong MJ, van der Meulen-de Jong AE, Romberg-Camps MJ, Becx MC, Maljaars JP, Cilissen M, van Bodegraven AA, Mahmmod N, Markus T, Hameeteman WM, Dijkstra G, Masclee AA, Boonen A, Winkens B, van Tubergen A, Jonkers DM, Pierik MJ.

Lancet. 2017 Sep 2;390(10098):959-968. doi: 10.1016/S0140-6736(17)31327-2. Epub 2017 Jul 14.

PMID:
28716313
27.

Habitual diet and diet quality in Irritable Bowel Syndrome: A case-control study.

Tigchelaar EF, Mujagic Z, Zhernakova A, Hesselink MAM, Meijboom S, Perenboom CWM, Masclee AAM, Wijmenga C, Feskens EJM, Jonkers DMAE.

Neurogastroenterol Motil. 2017 Dec;29(12). doi: 10.1111/nmo.13151. Epub 2017 Jul 17.

PMID:
28714091
28.

Biomarkers for visceral hypersensitivity in patients with irritable bowel syndrome.

Mujagic Z, Jonkers DMAE, Ludidi S, Keszthelyi D, Hesselink MA, Weerts ZZRM, Kievit RN, Althof JF, Leue C, Kruimel JW, van Schooten FJ, Masclee AAM.

Neurogastroenterol Motil. 2017 Dec;29(12). doi: 10.1111/nmo.13137. Epub 2017 Jul 3.

PMID:
28675524
29.

Intestinal Fungal Dysbiosis Is Associated With Visceral Hypersensitivity in Patients With Irritable Bowel Syndrome and Rats.

Botschuijver S, Roeselers G, Levin E, Jonkers DM, Welting O, Heinsbroek SEM, de Weerd HH, Boekhout T, Fornai M, Masclee AA, Schuren FHJ, de Jonge WJ, Seppen J, van den Wijngaard RM.

Gastroenterology. 2017 Oct;153(4):1026-1039. doi: 10.1053/j.gastro.2017.06.004. Epub 2017 Jun 15.

PMID:
28624575
30.

Early Life Exposure, Lifestyle, and Comorbidity as Risk Factors for Microscopic Colitis: A Case-Control Study.

Verhaegh BPM, Pierik MJ, Goudkade D, Cuijpers YSMT, Masclee AAM, Jonkers DMAE.

Inflamm Bowel Dis. 2017 Jun;23(6):1040-1046. doi: 10.1097/MIB.0000000000001103.

PMID:
28471835
31.

A 20-Year Temporal Change Analysis in Incidence, Presenting Phenotype and Mortality, in the Dutch IBDSL Cohort-Can Diagnostic Factors Explain the Increase in IBD Incidence?

van den Heuvel TRA, Jeuring SFG, Zeegers MP, van Dongen DHE, Wolters A, Masclee AAM, Hameeteman WH, Romberg-Camps MJL, Oostenbrug LE, Pierik MJ, Jonkers DM.

J Crohns Colitis. 2017 Oct 1;11(10):1169-1179. doi: 10.1093/ecco-jcc/jjx055.

PMID:
28430884
32.

Time trends in the epidemiology and outcome of perianal fistulizing Crohn's disease in a population-based cohort.

Göttgens KW, Jeuring SF, Sturkenboom R, Romberg-Camps MJ, Oostenbrug LE, Jonkers DM, Stassen LP, Masclee AA, Pierik MJ, Breukink SO.

Eur J Gastroenterol Hepatol. 2017 May;29(5):595-601. doi: 10.1097/MEG.0000000000000840.

PMID:
28350751
33.

The potential of volatile organic compounds for the detection of active disease in patients with ulcerative colitis.

Smolinska A, Bodelier AG, Dallinga JW, Masclee AA, Jonkers DM, van Schooten FJ, Pierik MJ.

Aliment Pharmacol Ther. 2017 May;45(9):1244-1254. doi: 10.1111/apt.14004. Epub 2017 Feb 26.

34.

Use of Rome criteria for the diagnosis of irritable bowel syndrome in primary care: a survey among European countries.

Mujagic Z, Jonkers DMAE, Hungin APS, de Wit NJ, Wensaas KA, Palka M, Leeters V, Kruimel JW, Leue C, Masclee AAM, Muris JWM.

Eur J Gastroenterol Hepatol. 2017 Jun;29(6):651-656. doi: 10.1097/MEG.0000000000000848.

PMID:
28125426
35.

Improvements in the Long-Term Outcome of Crohn's Disease Over the Past Two Decades and the Relation to Changes in Medical Management: Results from the Population-Based IBDSL Cohort.

Jeuring SF, van den Heuvel TR, Liu LY, Zeegers MP, Hameeteman WH, Romberg-Camps MJ, Oostenbrug LE, Masclee AA, Jonkers DM, Pierik MJ.

Am J Gastroenterol. 2017 Feb;112(2):325-336. doi: 10.1038/ajg.2016.524. Epub 2016 Dec 6.

PMID:
27922024
36.

Comment: Association Between Proton Pump Inhibitors and Microscopic Colitis: Implications for Practice and Future Research.

Verhaegh BPM, Pierik MJ, Jonkers DMAE.

Ann Pharmacother. 2017 Aug;51(8):718. doi: 10.1177/1060028016682974. Epub 2017 Apr 16. No abstract available.

PMID:
27903770
37.

On the External Validity of Epidemiologic Data from Hospital-based IBD Cohorts.

van den Heuvel TR, Pierik MJ, Jonkers DM.

J Crohns Colitis. 2016 Nov;10(11):1372-1373. Epub 2016 Apr 16. No abstract available.

PMID:
27085079
38.

The fecal microbiota as a biomarker for disease activity in Crohn's disease.

Tedjo DI, Smolinska A, Savelkoul PH, Masclee AA, van Schooten FJ, Pierik MJ, Penders J, Jonkers DM.

Sci Rep. 2016 Oct 13;6:35216. doi: 10.1038/srep35216.

39.

A novel biomarker panel for irritable bowel syndrome and the application in the general population.

Mujagic Z, Tigchelaar EF, Zhernakova A, Ludwig T, Ramiro-Garcia J, Baranska A, Swertz MA, Masclee AA, Wijmenga C, van Schooten FJ, Smolinska A, Jonkers DM.

Sci Rep. 2016 Jun 6;6:26420. doi: 10.1038/srep26420.

40.

Inflammatory bowel disease, cancer and medication: Cancer risk in the Dutch population-based IBDSL cohort.

van den Heuvel TR, Wintjens DS, Jeuring SF, Wassink MH, Romberg-Camps MJ, Oostenbrug LE, Sanduleanu S, Hameeteman WH, Zeegers MP, Masclee AA, Jonkers DM, Pierik MJ.

Int J Cancer. 2016 Sep 15;139(6):1270-80. doi: 10.1002/ijc.30183. Epub 2016 May 31.

41.

Editorial: additional evidence for drug-induced microscopic colitis - authors' reply.

Verhaegh BP, Pierik MJ, Jonkers DM.

Aliment Pharmacol Ther. 2016 Jun;43(12):1344-5. doi: 10.1111/apt.13640. No abstract available.

42.

Volatile organic compounds in breath as markers for irritable bowel syndrome: a metabolomic approach.

Baranska A, Mujagic Z, Smolinska A, Dallinga JW, Jonkers DM, Tigchelaar EF, Dekens J, Zhernakova A, Ludwig T, Masclee AA, Wijmenga C, van Schooten FJ.

Aliment Pharmacol Ther. 2016 Jul;44(1):45-56. doi: 10.1111/apt.13654. Epub 2016 May 2.

43.

Microbial perturbations and modulation in conditions associated with malnutrition and malabsorption.

Jonkers DM.

Best Pract Res Clin Gastroenterol. 2016 Apr;30(2):161-72. doi: 10.1016/j.bpg.2016.02.006. Epub 2016 Feb 10. Review.

PMID:
27086883
44.

Is intestinal oxidative stress involved in patients with compensated liver cirrhosis?

Pijls KE, Jonkers DM, Elizalde M, Drittij-Reijnders MJ, Haenen GR, Bast A, Masclee AA, Koek GH.

Ann Hepatol. 2016 May-Jun;15(3):402-9. doi: 10.5604/16652681.1198816.

45.

High risk of drug-induced microscopic colitis with concomitant use of NSAIDs and proton pump inhibitors.

Verhaegh BP, de Vries F, Masclee AA, Keshavarzian A, de Boer A, Souverein PC, Pierik MJ, Jonkers DM.

Aliment Pharmacol Ther. 2016 May;43(9):1004-13. doi: 10.1111/apt.13583. Epub 2016 Mar 9.

46.

Epidemiology and Long-term Outcome of Inflammatory Bowel Disease Diagnosed at Elderly Age-An Increasing Distinct Entity?

Jeuring SF, van den Heuvel TR, Zeegers MP, Hameeteman WH, Romberg-Camps MJ, Oostenbrug LE, Masclee AA, Jonkers DM, Pierik MJ.

Inflamm Bowel Dis. 2016 Jun;22(6):1425-34. doi: 10.1097/MIB.0000000000000738.

PMID:
26933752
47.

Plasma intestinal fatty acid-binding protein fails to predict endoscopic disease activity in inflammatory bowel disease patients.

Bodelier AG, Pierik MJ, Lenaerts K, de Boer E, Olde Damink SW, Hameeteman WM, Masclee AA, Jonkers DM.

Eur J Gastroenterol Hepatol. 2016 Jul;28(7):807-13. doi: 10.1097/MEG.0000000000000616.

PMID:
26919325
48.

Editorial: serotonin and irritable bowel syndrome--reconciling pharmacological effects with basic biology; authors' reply.

Mujagic Z, Keszthelyi D, Thijssen AY, Jonkers DM, Masclee AA.

Aliment Pharmacol Ther. 2016 Mar;43(5):646-7. doi: 10.1111/apt.13506. No abstract available.

49.

A profile of volatile organic compounds in exhaled air as a potential non-invasive biomarker for liver cirrhosis.

Pijls KE, Smolinska A, Jonkers DM, Dallinga JW, Masclee AA, Koek GH, van Schooten FJ.

Sci Rep. 2016 Jan 29;6:19903. doi: 10.1038/srep19903.

50.

Alterations in serotonin metabolism in the irritable bowel syndrome.

Thijssen AY, Mujagic Z, Jonkers DM, Ludidi S, Keszthelyi D, Hesselink MA, Clemens CH, Conchillo JM, Kruimel JW, Masclee AA.

Aliment Pharmacol Ther. 2016 Jan;43(2):272-82. doi: 10.1111/apt.13459. Epub 2015 Nov 5.

Supplemental Content

Loading ...
Support Center